[Polycystic ovary--classification and treatment by bromocriptine]

Area of Science:

• Endocrinology
• Reproductive Medicine
• Metabolic Disorders

Context:

• Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized by hyperandrogenism.
• Current classification methods for PCOS may not fully capture its diverse etiologies.
• Understanding the specific hormonal profiles in PCOS is crucial for effective management.

Purpose:

• To classify PCOS into distinct 'ovarian' and 'adrenal' types based on plasma androstenedione (A) and dehydroepiandrosterone sulfate (DHAS) levels.
• To investigate the hormonal characteristics, treatment responses, and ovulation induction success rates for each PCOS type.

Summary:

• Plasma A and DHAS levels were analyzed in 29 women with PCOS.
• Elevated A and/or DHAS were observed in all participants.
• Women were classified as 'ovarian type' (DHAS < 2,000 ng/ml, A > 1.4 ng/ml) or 'adrenal type' (DHAS > 2,000 ng/ml). Both types exhibited elevated LH and exaggerated LH response to LHRH.
• Dexamethasone reduced DHAS but not A levels.
• Ovulation induction rates varied: clomiphene (20% ovarian, 33% adrenal), bromocriptine (8/9 ovarian, 1/6 adrenal). Bromocriptine-resistant adrenal types responded to clomiphene and prednisolone.
• This classification provides insights into PCOS pathogenesis and guides treatment strategies.

Impact:

• The proposed classification of PCOS into ovarian and adrenal types offers a more nuanced approach to understanding the condition.
• This classification demonstrates utility in predicting treatment responses, particularly for ovulation induction.
• The findings contribute to a better understanding of the pathogenesis of PCOS and personalized therapeutic interventions.